• Corpus ID: 22640759

Treatment of Crohn's disease with cannabis: an observational study.

  title={Treatment of Crohn's disease with cannabis: an observational study.},
  author={Timna Naftali and Lihi Bar Lev and Doron Yablecovitch and Elizabeth E. Half and Fred Meir Konikoff},
  journal={The Israel Medical Association journal : IMAJ},
  volume={13 8},
BACKGROUND The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn's disease (CD) was ever published. OBJECTIVES To describe the effects of cannabis use in patients suffering from CD. METHODS In this retrospective observational study we examined disease activity, use of medication, need for surgery, and hospitalization before and after cannabis use in 30 patients (26 males… 

Tables from this paper

Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.

Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.

Cannabis use by inflammatory bowel disease patients can induce clinical improvement and is associated with reduced use of medication and slight weight gain, and most patients respond well to a dose of 30 g/month, or 21 mg Δ9-tetra- hydrocannabinol and 170 mg Cannabidiol (CBD) per day.

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey.

This survey reveals the largest data set on cannabis use among IBD patients in Germany, with the potential for further research, mainly procured from the black market, with unknown quality.

Association Between Cannabis Use and Complications Related to Crohn’s Disease: A Retrospective Cohort Study

Cannabis use may mitigate several of the well-described complications of Crohn’s disease among hospital inpatients, and could possibly be through the effect of cannabis in the endocannabinoid system.

Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn's Disease

Cannabis use is common in patients with IBD and subjectively improved pain and diarrheal symptoms, however, Cannabis use was associated with higher risk of surgery in Patients with Crohn's disease.

Cannabis for Inflammatory Bowel Disease

Evidence is gathering that manipulating the endocannabinoid system can have beneficial effects in IBD, but further research is required to declare cannabinoids a medicine.

An overview of cannabis based treatment in Crohn’s disease

  • T. Naftali
  • Biology, Medicine
    Expert review of gastroenterology & hepatology
  • 2020
Cannabis seems to have a therapeutic potential in IBD, and this potential must not be neglected; however, cannabis research is still at a very early stage and more studies investigating the effect of the various cannabis compounds are needed.

Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.

Short term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis, however, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

The preclinical data, clinical data, safety data, and the regulatory landscape as they apply to medical cannabis use in inflammatory bowel disease are summarized.



Adverse effects of medical cannabinoids: a systematic review

Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events, and high-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids.

Effects of cannabis on pulmonary structure, function and symptoms

Smoking cannabis was associated with a dose-related impairment of large airways function resulting in airflow obstruction and hyperinflation and the 1:2.5–5 dose equivalence between cannabis joints and tobacco cigarettes for adverse effects on lung function is of major public health significance.

Cannabinoids in Clinical Practice

Cannabis is frequently used by patients with multiple sclerosis for muscle spasm and pain, and in an experimental model of MS low doses of cannabinoids alleviated tremor, and an examination of psychiatric hospital admissions found no evidence of psychosis, however, it may exacerbate existing symptoms.

Effects of cannabis on lung function: a population-based cohort study

Cannabis use was associated with higher lung volumes, suggesting hyperinflation and increased large-airways resistance, but there was little evidence for airflow obstruction or impairment of gas transfer.

Anti-inflammatory therapies

The early use of prophylactic anti-inflammatory agents is advocated in the treatment of chronic asthma and it is hoped that this treatment scheme will result in a reduction in the morbidity and mortality from this common chronic condition.

The cannabinergic system as a target for anti-inflammatory therapies.

Therapeutic opportunities for a variety of inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, allergic asthma, and autoimmune diabetes through modulation of the endocannabinoid system are suggested.

Pharmacological actions and therapeutic uses of cannabis and cannabinoids

This review highlights the pharmacology, pharmacokinetics, pharmacological actions, therapeutic uses and adverse effects of cannabinoids, and the possible clinical applications of these ligands.